◼ Archived
Business
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
2 trends tracked about this subject — the full history, oldest to newest below.
Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine.
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.